semaglutide oral cardiovascular indication 2025 news The FDA has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, for weight loss and long-term weight maintenance in certain adult patients—in just 54 days from filing Oral semaglutide reduces risk of

Most Common Side Effects: Nausea and vomiting Frequently reported, especially when increasing the dose

This immune response leads to inflammation in the joints, which can cause significant discomfort and, over time, may lead to joint damage and other complications

Min JS, Jo SJ, Lee S, et al

The growth follows a significant May ruling in which the court allowed key expert testimony regarding gastroparesis and other gastrointestinal injuries to proceed, preserving important evidence for plaintiffs as the litigation moves forward

It is approved for chronic weight management in adults and children 6 years and older with obesity due to specific genetic conditions, including proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome